<i>In Vitro</i> Time-Kill Studies of Trimethoprim/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli Using Cation-Adjusted Mueller-Hinton Broth and ISO-Sensitest Broth-Reference-Cited by-同舟云学术

In Vitro Time-Kill Studies of Trimethoprim/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli Using Cation-Adjusted Mueller-Hinton Broth and ISO-Sensitest Broth

Published:2022-03-15 Issue:3 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lasko Maxwell J.¹,Gethers Matthew L.¹,Tabor-Rennie Jennifer L.¹,Nicolau David P.¹²^ORCID,Kuti Joseph L.¹^ORCID

Affiliation:

1. Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA

2. Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA

Abstract

Trimethoprim/sulfamethoxazole (TMP/SMZ) is considered the treatment of choice for infections caused by Stenotrophomonas maltophilia , but limited pharmacodynamic data are available to support current susceptibility breakpoints or guide optimal dosing. Time-kill studies using a TMP/SMZ concentration of 4/40 μg/mL were conducted to compare 4 S. maltophilia with 4 Escherichia coli isolates having the same MICs (0.25/4.75 to 4/76 μg/mL) in cation-adjusted Mueller-Hinton broth (CAMHB) and ISO-Sensitest broth (ISO broth).

Funder

HHS | U.S. Food and Drug Administration

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.02167-21

Reference34 articles.

1. The Burden of Bloodstream Infections due to Stenotrophomonas Maltophilia in the United States: A Large, Retrospective Database Study

2. Advances in the Microbiology of Stenotrophomonas maltophilia

3. Comparative in vitro activity of sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim and other agents against multiresistant Gram-negative bacteria

4. Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen

5. Clinical and Laboratory Standards Institute. 2021. Performance standards for antimicrobial susceptibility testing, 31st ed, CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long Story Short: Establishing Breakpoints for Antimicrobials and 2023 Updates;Current Infectious Disease Reports;2024-01-18

2. Treatment approaches for severe Stenotrophomonas maltophilia infections;Current Opinion in Infectious Diseases;2023-10-16

3. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections;Clinical Infectious Diseases;2023-07-18

4. Steno‐sphere: Navigating the enigmatic world of emerging multidrug‐resistantStenotrophomonas maltophilia;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2023-06-08

5. Trimethoprim/sulfamethoxazole pharmacodynamics against Stenotrophomonas maltophilia in the in vitro chemostat model;Journal of Antimicrobial Chemotherapy;2022-09-14